Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio

Why It Matters

The upgraded target underscores investor confidence and positions COLL as a compelling play in the expanding abuse‑deterrent opioid market, potentially driving share price appreciation.

Key Takeaways

• Truist raised COLL price target to $58, maintains Buy rating
• Jornay PM projected to deliver $190‑$200 million in 2026 sales
• Full‑year 2026 revenue forecast: $805‑$825 million
• Adjusted EBITDA expected at $455‑$475 million
• Robust pain portfolio supports long‑term earnings momentum

Pulse Analysis

Collegium Pharmaceutical’s recent price‑target hike by Truist reflects a broader market shift toward safer opioid solutions. As regulators and payers tighten scrutiny on traditional opioids, abuse‑deterrent formulations like Jornay PM gain traction, offering clinicians a therapeutic option that balances efficacy with reduced misuse risk. This regulatory tailwind, combined with the company’s focused R&D pipeline, strengthens its competitive moat and justifies the elevated valuation.

The 2026 financial outlook paints a picture of disciplined growth. Projected net product revenue of $805‑$825 million, anchored by Jornay PM’s $190‑$200 million contribution, signals that the drug is moving beyond launch hype into a revenue‑generating engine. Meanwhile, an adjusted EBITDA range of $455‑$475 million suggests robust margin expansion, likely driven by cost‑control measures and scaling efficiencies across the portfolio. Investors will watch whether the company can sustain this trajectory amid evolving payer dynamics.

Beyond the numbers, Collegium’s strategic emphasis on a diversified pain‑management suite positions it well for long‑term resilience. By blending abuse‑deterrent opioids with non‑opioid modalities, the firm mitigates concentration risk and taps multiple market segments. This balanced approach, coupled with a clear earnings roadmap through 2026, makes COLL a noteworthy candidate for portfolios seeking exposure to innovative pharma solutions with upside potential.